Albireo Pharma Inc RPE
What is the RPE of Albireo Pharma Inc?
The RPE of Albireo Pharma Inc is $441.469k
What is the definition of RPE?
Revenue per employee (RPE) is revenue divided by the number of employees of an organization.
= net income / number of employees
RPE of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Companies with rpe similar to Albireo Pharma Inc
- Sanofi has RPE of €440.466k
- Sanofi has RPE of €440.466k
- Ashtead Plc has RPE of $440.641k
- Baofeng Modern International has RPE of ¥440.836k
- GreenSky Inc has RPE of $441.290k
- The Heavitree Brewery PLC has RPE of £441.375k
- Albireo Pharma Inc has RPE of $441.469k
- SB Inc has RPE of $441.496k
- LendingTree has RPE of $441.727k
- Yu Tak International has RPE of HKD$441.739k
- Jiumaojiu International has RPE of ¥441.807k
- Anaergia Inc has RPE of CAD$441.932k
- AMG Advanced Metallurgical NV has RPE of $441.948k